According to recent reporting, Gov. Josh Shapiro is considering cutting off access to the weight loss drugs like Zepbound and Wegovy to all Medicaid recipients in the state who are not dangerously ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

U.S. energy firms seek exemption from Trump to transport LNG on U.S.-built ships. China Airlines orders Boeing passenger and ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Gray, or gray market medications, are nothing new, and GLP-1s — the class of weight loss wonder drug that includes ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...